Product Description: Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405-10.
CAS Number: 357613-77-5
Molecular Weight: N/A
Compound Purity: 99.23
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: CD28